Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07685548 | AI-Driven Tumor Response Evaluation for Solid Tumors | not yet recruiting | — | 6,120 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07689240 | Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma | not yet recruiting | Phase 3 | 400 | National Cancer Institute (NCI)NIH | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07689721 | ctDNA-Guided Intraventricular Therapy for CNS Malignancies(GUIDE-CNS) | not yet recruiting | N/A | 77 | Alireza MansouriOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07621484 | HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer | not yet recruiting | Phase 2 | 48 | Shanghai Changzheng HospitalOTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07675187 | HCC Risk and Monitoring in Patients With Type 2 Diabetes(GAAD-DM) | not yet recruiting | N/A | 2,400 | National Taiwan University HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07686185 | A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs. | not yet recruiting | — | 500 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07686744 | Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma(NPVPP) | not yet recruiting | Phase 1 | 8 | Jian LinOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07687914 | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 50 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07688291 | A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy | not yet recruiting | Phase 2 | 40 | Beijing GoBroad HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07688577 | XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 140 | Xilio Development, Inc.INDUSTRY | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07682649 | Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer(ESCENDO) | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07682675 | Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck(ZANACC) | not yet recruiting | Phase 2 | 51 | UNICANCEROTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683013 | Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 18 | Hyundai Bioscience Co., Ltd.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683507 | Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Feng LiuOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07684170 | Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms | not yet recruiting | Phase 2 | 58 | Compass TherapeuticsINDUSTRY | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07685041 | An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer | not yet recruiting | Phase 1 | 24 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07685197 | Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC | not yet recruiting | Phase 2 | 100 | Zhou ChengzhiOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07685704 | Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study | not yet recruiting | Phase 2 | 46 | Zhifeng Zhao, PhDOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07671937 | INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study(INSPIRE) | not yet recruiting | N/A | 2,748 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07680088 | Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer | not yet recruiting | Phase 2 | 17 | University of Texas Southwestern Medical CenterOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT07682454 | Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | not yet recruiting | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07032701 | A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer | not yet recruiting | N/A | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07667296 | APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 826 | Aveta Biomics, Inc.INDUSTRY | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07675876 | Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer(CS) | not yet recruiting | Phase 1 | 10 | Carcinex IncINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678580 | Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 50 | Tang-Du HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07679997 | Trilaciclib Combined With Immunochemotherapy for R/M HNSCC | not yet recruiting | Phase 2 | 32 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | not yet recruiting | Phase 1 | 19 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675733 | A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility(SHORTEN) | not yet recruiting | N/A | 30 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07545460 | A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07662811 | SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 396 | Shanghai Chest HospitalOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07672431 | Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression | not yet recruiting | N/A | 24 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672782 | Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | not yet recruiting | Phase 2 | 28 | GOG FoundationNETWORK | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673393 | Improving Prognostication in Colon Cancer(MARBLE) | not yet recruiting | — | 400 | Universitaire Ziekenhuizen KU LeuvenOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07674121 | PROLONG (PRostateOLaparibONcombinationGcc) Study(PROLONG) | not yet recruiting | — | 75 | AstraZenecaINDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07674524 | Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC | not yet recruiting | — | 160 | Sun Yat-sen UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07674693 | Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases | not yet recruiting | Phase 1 | 29 | NYU Langone HealthOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07674706 | Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers | not yet recruiting | N/A | 50 | National University Hospital, SingaporeOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07110233 | Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma | not yet recruiting | N/A | 64 | University of California, San FranciscoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07670442 | Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy(EPICIRC-SCLC) | not yet recruiting | — | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07670715 | Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07670962 | Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy | not yet recruiting | — | 300 | Asan Medical CenterOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07671573 | Integrated Early-CARE for Head & Neck Cancer.(i-CARE-HN) | not yet recruiting | N/A | 64 | Portuguese Oncology Institute, CoimbraOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07671690 | Prediction of Neoadjuvant Therapy Efficacy and Prognosis for Breast Cancer Based on Multimodal Data | not yet recruiting | N/A | 1,800 | Yunnan Cancer HospitalOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07672223 | A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 3 | 570 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07645846 | Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma(PANDA) | not yet recruiting | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07663747 | Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC(FIDELIO) | not yet recruiting | Phase 2 | 56 | The Netherlands Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07667608 | Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings | not yet recruiting | — | 120 | Assiut UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 36 | Hebei Medical University Fourth HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2026source: clinicaltrials